This week: our original analysis reveals psychedelics company spending trends; Morgan Stanley identifies psychedelics as disruptive theme; COMPASS Pathways rallies; and more…

This week: our latest Special Report goes inside the challenge to DEA’s proposed scheduling of 5 tryptamines; we take a look at the latest company to enter a ‘death spiral financing’; and more…

This week: the highly-anticipated Netflix adaptation of Pollan’s How to Change Your Mind hits Netflix; 2 amendments to the NDAA that provide scope for psychedelic research are adopted by the House; Stanford Summer Course explores psychedelic policy perspectives; and more…

This week: Pollan’s ‘How to Change Your Mind’ comes to Netflix this week; DEA schedules a rare public hearing on its proposed scheduling of five psychedelics; and more…

This week: we have guest commentary from JHU’s Sandeep Nayak, who has led reanalysis of the NEJM psilocybin vs. escitalopram trial; Oregon Psilocybin Training tuition fees are out; we look at how off-label use may play out; and more…

This week: COMPASS Pathways survives challenges to two of its patents covering Polymorph A; MindMed is granted a patent covering candyflipping; we look at whether psychedelics companies will protect access to abortions; and more…